DeFloria LLC Commences Phase 1 Clinical Program for Innovative Full Spectrum Hemp Botanical Drug
We are proud of our team's hard work reach this point, and I am excited to help develop the Phase 2 program for this new drug."
- We are proud of our team's hard work reach this point, and I am excited to help develop the Phase 2 program for this new drug."
- "The initiation of the AJA001 clinical program serves as an important milestone for DeFloria.
- At DeFloria, we have united the early leaders in CBD with the finest minds in clinical and biotechnological research.
- Following completion of this Phase 1 study, DeFloria plans to submit an Investigational New Drug (IND) application to the Food and Drug Administration (FDA) to commence the Phase 2 clinical program for AJA001.